Farmers discover innovative method to save millions of gallons of water: 'Farmers can irrigate their fields while sitting on a beach'
An assessment made by researchers from the University of Florida's Institute of Food and Agricultural Sciences has proved that a years-long campaign to educate regional farmers about the benefits of irrigation has paid off.
"We're flirting with saving more than 696 million gallons of water each year if the farmers of all 8,000 acres of watermelon in the region adopt this technology," said Tyler Pittman, the UF/IFAS agriculture and natural resources agent who conducted the assessment.
According to the United Nations, 70% of the world's freshwater is used for agriculture, and 40% of that has been wasted due to poor irrigation systems, evaporation, and insufficient water management.
Efficiently managing irrigation is essential for commercial watermelon growers, and UF/IFAS recommends that short, frequent irrigation helps maximize water absorption while minimizing water and nutrient leaching.
Not only has this information campaign helped reduce water waste for farmers, but it has also shortened their time in the field by around 1.7 hours, according to the report's data.
Extreme weather, including severe droughts, is being driven by rising global temperatures. The resulting impacts on freshwater supplies are far and wide, with over 2.2 billion people across the globe lacking access to safely managed drinking water services, per the UN.
By shifting to wireless automation equipment, farmers have been able to reduce irrigation run times by 1.4 hours per day, significantly cutting water waste.
"Farmers can irrigate their fields while sitting on a beach on an island somewhere," Pittman said in the report. "All they need is an internet connection."
Agricultural robots like the Roboton Farmer have also made an impact on the farming sector. This crop-tending bot uses AI to help it do a variety of tasks — including seeding, watering, and weeding — while using renewable solar power instead of dirty diesel fuel.
Would you take a gardening class if it were free?
Heck yes!
If it fits into my schedule
Maybe
Probably not
Click your choice to see results and speak your mind.
Watermelons are 92% water, as the Mayo Clinic observed, which means that efficient water management is key in their growth. They're also high in lycopene, which is an antioxidant linked to decreased risk of cancer and heart disease, making them part of a healthy diet.
According to the UF/IFAS report, farmers have had financial help from assistance programs offered by the Office of Agricultural Water Policy and the Suwannee River Water Management District.
Two-thirds of farmers surveyed stated that the support was key in making the upgrade to automation; more than half of the farmers received over $10,000 to help purchase the equipment.
"If it wasn't for cost share, there's no way I would have thought about trying automation," said Garrett Beach, a local watermelon farmer.
He shifted to automated irrigation for 600 acres of watermelon in 2023, and although he initially oversaw the operations manually, the technology won him over.
"Now, I trust it, and I see its value," Beach added. "I won't farm without it from now on."
Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
4 days ago
- Newsweek
Cancer Vaccine Breakthrough: What We Know About 'Exciting' Early Data
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Researchers at the University of Florida are moving closer to developing what they have described as a "universal" cancer vaccine, according to a study published in Nature Biomedical Engineering on July 18. The vaccine would work by "waking the immune system up against something that looks dangerous, and then that response spills over to recognize and reject the tumor," Dr. Elias Sayour, co-author of the study, director of the Pediatric Cancer Immunotherapy Initiative, and principal investigator at the RNA Engineering Laboratory at the University of Florida, told Newsweek. Sayour said that he believed the vaccine would apply to all types of cancer, because the treatment would result in the immune system being able to "recognize and reject all forms of cancer." "In active cancers, the immune system has been fooled or lies dormant," he said. "This approach can wake it up, restoring it in the fight against cancer." Sayour said that the concept of the treatment is being investigated in ongoing clinical human trials. If all goes well, it "could be a completely new paradigm to treat all cancer patients." Photo-illustration by Newsweek/Getty Most people think of vaccines as being "preventive," and taken to "prevent or lessen the impact of certain infectious diseases," David Braun, a professor of medicine and member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, told Newsweek. While there are some efforts in this field for cancer, the majority of trials investigate "therapeutic" vaccines, which are used to try to treat cancer once it develops, he said. "Most cancer vaccines try to steer the immune system to attack a patient's cancer, which makes it very difficult to create a universal vaccine," Braun, who is not associated with the study, said. Referring to the study, Braun said the research team is proposing "the idea that the vaccination itself, somewhat irrespective of what it is targeting, might stimulate the immune system enough to attack cancer." "It is a very intriguing idea, but would need to be tested very carefully in clinical studies," he added. What Does This Mean for Cancer Treatment? Almost 2 million new cancer cases were reported in the United States in 2022. In 2023, more than 600,000 people died of cancer, according to the Centers for Disease Control and Prevention (CDC) data. Cancer is the second leading cause of death in the U.S., behind heart disease. In 2022, cancer accounted for almost 19 percent of deaths in the country, according to Statista data. Cancer vaccines have been approved in the past, such as Provenge, the Seattle biotech company Dendreon's shot used to treat certain forms of advanced prostate cancer. There are also others currently undergoing the clinical trial process, such as Moderna's experimental mRNA-4157 cancer vaccine, which aims to prevent the recurrence of melanoma and lung cancer and has progressed to Phase 3 in its clinical trials. However, what makes this new study notable is the fact that it is one step closer to researchers finding a vaccine to treat all types of cancer, rather than a specific type. "This strategy could be a promising neoadjuvant therapy prior to checkpoint blockades or other cancer therapies," Hua Wang, a professor of materials science and engineering at the University of Illinois Urbana-Champaign, told Newsweek. "With more success of personalized cancer vaccines, the researchers, clinicians, and the patient community will hopefully gain more confidence in cancer vaccines," Wang, who is not associated with the study, said. "At that stage, the goal of developing a universal cancer vaccine will be more reachable." Braun deemed the study "exciting early data," but told Newsweek it still has "a long path to having a major impact on the treatment of cancers in individuals." Potential Challenges While the findings are a "promising" breakthrough in cancer research, Wang said that still "rigorous safety evaluations and the optimization for therapeutic benefits are needed before this strategy can move forward." "Generally speaking, every one of us is hoping for a universal cancer vaccine that can treat or prevent different types of cancers," he said. However, Wang added that practically, "personalized" cancer vaccines are "more likely to cross the finish line because of the higher specificity and thus less off-target effects." While many types of cancer vaccines are currently being tested in clinical trials, Wang said that the challenge largely lies in "the balance of therapeutic benefits and safety." Another key issue is that "very few researchers have the resources and support needed to push forward a clinical trial on cancer vaccine," he added. Braun also said that, while cancer vaccines hold "tremendous promise," they also raise a number of open questions. "What are the best targets for the vaccine, or are more universal vaccines possible?" he said. "In what setting would a vaccine be most effective? What other types of treatments should be given together with the vaccine?" He added that in the coming years, "it will be critical to answers these questions while also having definitive clinical studies to prove that cancer vaccines help patients to live longer." Full Interview Below Q1: What does this study mean for the general public? How could this change the prevalence and treatment of cancer? Hua Wang, a professor of materials science and engineering at the University of Illinois Urbana-Champaign: "This paper reports that the early stimulation of IFN-I pathways could increase the sensitivity of poorly-immunogenic tumors to checkpoint blockades. The researchers performed the IFN-I stimulation by using unmodified mRNAs (without a specific target). This strategy could be a promising neoadjuvant therapy prior to checkpoint blockades or other cancer therapies. However, rigorous safety evaluations and the optimization for therapeutic benefits are still needed before this strategy can move forward." David Braun, a professor of medicine and member of the Center of Molecular and Cellular Oncology at Yale Cancer Center: "This study has two important goals: (1) to understand why current immune-based treatments work so well in some patients, and (2) to try to use that knowledge to design new immune treatments. In animal models, the research team is able to make tumors more sensitivity to immune therapy using this new approach. While exciting early data, we do have to remember that this is early work in animal studies, and so there is still a long path to having a major impact on the treatment of cancers in individuals." Q2: How long do you think it will be before a universal cancer vaccine is made? Wang: "Generally speaking, every one of us is hoping for a universal cancer vaccine that can treat or prevent different types of cancers. However, practically, personalized cancer vaccines are more likely to cross the finish line because of the higher specificity and thus less off-target effects. With more success of personalized cancer vaccines, the researchers, clinicians, and the patient community will hopefully gain more confidence in cancer vaccines. At that stage, the goal of developing a universal cancer vaccine will be more reachable." Braun: "When most people think of vaccines, they think of 'preventive' vaccines—the kind that children and adults typically receive to prevent or lessen the impact of certain infectious diseases. While there are some of those efforts in cancer as well, the majority of efforts are focused on 'therapeutic' vaccines, which are used to try to treat cancer once it develops. Most cancer vaccines try to 'steer' the immune system to attack a patient's cancer, which makes it very difficult to create a universal vaccine. In this study, the research team proposes a major general form of vaccination—the idea that the vaccination itself, somewhat irrespective of what it is targeting, might stimulate the immune system enough to attack cancer. It is a very intriguing idea, but would need to be tested very carefully in clinical studies." Q3: Can you foresee any challenges in the development of a cancer vaccine? If so, what are they? Wang: "Various types of cancer vaccines including neoantigen mRNA vaccines, dendritic cell vaccines, tumor exosome vaccines, nanomaterial vaccines, and biomaterial scaffold vaccines are being tested in clinical trials at the moment. The challenge largely lies in the balance of therapeutic benefits and safety, and varies for each vaccine platform. One dramatic challenge, in my opinion, is the overwhelming bar to pursuing the clinical translation of promising cancer vaccines. Very few researchers have the resources and support needed to push forward a clinical trial on cancer vaccine." Braun: "Cancer vaccines hold tremendous promise to 'steer' the immune system to attack cancer cells, but there are a number of open questions. What are the best targets for the vaccine, or are more 'universal' vaccines possible? In what setting would a vaccine be most effective? What other types of treatments should be given together with the vaccine? In the coming years, it will be critical to answer these questions while also having definitive clinical studies to prove that cancer vaccines help patients to live longer."
CNBC
4 days ago
- CNBC
Healthy Returns: Researchers move closer to a universal cancer vaccine
A universal cancer vaccine – what once seemed like a pipe dream – may be inching closer to becoming reality. On Friday, University of Florida researchers said findings from a new study could lead to the development of a universal shot that can jumpstart the immune system to fight cancer. The study in mice, published in Nature Biomedical Engineering, showed that an experimental mRNA vaccine boosted the tumor-fighting effects of a common cancer drug called immune checkpoint inhibitors. The vaccine is not designed for a specific virus or cancer cells, but engineered to "wake up" the immune system against the disease, "spurring it to respond as if fighting a virus," according to a UF release. "What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction," Dr. Duane Mitchell, a co-author of the study and professor of neurosurgery at the university's College of Medicine, said in the release. That's unlike current approaches to cancer vaccines, which involve finding a target expressed by many cancer patients or, in the case of Moderna and Merck, developing personalized vaccines tailored to each patient's specific tumor. The universal vaccine has the potential to be used broadly across cancer patients, "even possibly leading us to an off-the-shelf cancer vaccine," Mitchell said. The UF researchers are still working to replicate the findings in humans. If they do, a one-size-fits-all vaccine could provide an alternative to surgery, radiation and chemotherapy. Here's how the vaccine works: The mRNA shot essentially tells the body to produce certain proteins that stimulate the immune system, including one called PD-L1, which is often found on the surface or inside of cancer cells. Those cells often use PD-L1 to hide from immune attacks. But by boosting PD-L1, the vaccine can actually make tumors more vulnerable to immune checkpoint inhibitors that block that protein, helping the immune system recognize and destroy the cancer. The study showed promising results on treatment-resistant tumors in skin cancers by combining the mRNA vaccine with a monoclonal antibody, a common immunotherapy drug that attempts to alert the immune system that a tumor is foreign and should be attacked. It also showed positive results when tested on mouse skin, bone and brain cancers as a solo treatment. In some cases, the tumors were eliminated entirely. "This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects," said senior author Dr. Elias Sayour, a UF Health pediatric oncologist, in a release. Feel free to send any tips, suggestions, story ideas and data to Annika at We're just days away from the peak of digital health earnings season, and this quarter is sure to be an interesting one. The two companies that went public earlier this year, Hinge Health and Omada Health, will report results for the first time since their debut. And since President Donald Trump's tax-and-spending bill passed and his Aug. 1 tariff deadline is approaching, we'll get some insight into how digital health companies have been operating against a volatile macroeconomic and policy backdrop. Here are some of the reports CNBC will be watching for: Hinge Health – Aug. 5 Omada Health – Aug. 7 Hims & Hers Health – Aug. 4 Doximity – Aug. 7 Teladoc Health – July 29 We'll have plenty to dive into in the coming weeks, so be sure to keep up with CNBC's coverage. Feel free to send any tips, suggestions, story ideas and data to Ashley at
Yahoo
4 days ago
- Yahoo
Florida Just Deployed 40 Robot Bunnies to Trick the Worst Predator in the Everglades
Florida's Burmese python problem isn't going away anytime soon. The researchers, snake trackers, and other conservationists working to remove the giant snakes will be the first to tell you that eradicating this invasive species isn't a realistic goal. That hasn't kept them from trying to manage the problem, though, and scientists are now working on a new and futuristic approach to finding and removing pythons: robotic bunny rabbits. Researchers at the University of Florida are hoping these robo-bunnies can be another tool in the python toolbox, similar to the highly successful scout-snake method that has been honed by wildlife biologists at the Conservancy of Southwest Florida. Only instead of using GPS-collared male pythons to lead them to the females, trackers would use the robots to bring the invasive snakes to them. These are stuffed toys that have been retro-fitted with electrical components so they can be remotely controlled. The robots also have tiny cameras that sense movement and notify researchers, who can then check the video feed to see if a python has been lured in. The University's experiments with robotic rabbits are ongoing, according to the Palm Beach Post, and the research is being funded by the South Florida Water Management District — the same government agency that pays bounties to licensed snake removal experts and hosts the Florida Python Challenge every year. 'Our partners have allowed us to trial these things that may sound a little crazy,' wildlife ecologist and UF project leader Robert McCleery told the Post. 'Working in the Everglades for ten years, you get tired of documenting the problem. You want to address it.' McCleery said that in early July, his team launched a pilot study with 40 robotic rabbits spread out across a large area. These high-tech decoys will be monitored as the team continues to learn and build on the experiment. (As one example, McCleery explained that incorporating rabbit scents into the robots could be worth consideration in the future.) Read Next: These Snake Trackers Have Removed More than 20 Tons of Invasive Pythons from Florida… and They're Just Getting Started The idea of using bunnies as decoys made sense for the team at UF, since rabbits, and specifically marsh rabbits, are some of the favorite prey items for Burmese pythons. Recent studies (including one authored by McCleery) have shown the massive declines in the Everglades' marsh rabbit populations that can be directly attributed to pythons. 'Years ago we were hearing all these claims about the decimation of mesomammals in the Everglades. Well, this researcher thought that sounded far-fetched, so he decided to study it,' says Ian Bartoszek, a wildlife biologist and python tracker based in Naples. 'So, he got a bunch of marsh rabbits, put [GPS] collars on them, and then he let them go in the core Everglades area … Within six months, 77 percent of those rabbits were found inside the bellies of pythons. And he was a believer after that.' Solve the daily Crossword
